Meningioma
Symptoms, Doctors, Treatments, Advances & More

Meningioma Overview

Save information for later
Sign Up

Learn About Meningioma

View Main Condition: Brain Tumor

What is the definition of Meningioma?
Meningiomas are tumors that originate in the meninges, the membranes that surround the brain and spinal cord. Most Meningiomas are not cancerous (benign), though a minority of Meningiomas can be classified as atypical or cancerous (malignant). Though rare, malignant Meningiomas can be highly aggressive. However, even benign Meningiomas can cause problems if their growth affects neighboring areas of the brain. Though most Meningiomas grow slowly, there is no way to predict the rate of growth for a particular Meningioma or to know how long a specific Meningioma was growing before it was diagnosed. Signs and symptoms can vary but may include seizures, headaches, weakness in the arms and legs, and vision loss. Sometimes memory loss, carelessness, and unsteadiness are the only symptoms.
What are the alternative names for Meningioma?
  • Meningioma
Who are the top Meningioma Local Doctors?
Elite in Meningioma
Dr. Stephen T. Magill
Neurosurgery
Elite in Meningioma
Dr. Stephen T. Magill
Neurosurgery
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
312-695-4360
Experience:
13+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Magill is a Neurosurgery provider practicing medicine in Chicago, Illinois. He has been practicing medicine for over 13 years. Dr. Magill is rated as an Elite provider by MediFind in the treatment of Meningioma. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Meningioma, Schwannoma, Brain Tumor, Rhizotomy, and Awake Craniotomy. Dr. Magill is board certified in American Board Of Neurological Surgery - Neurological Surgery (Certified).

Elite in Meningioma
Dr. Paul A. Gardner
Neurosurgery
Elite in Meningioma
Dr. Paul A. Gardner
Neurosurgery

UPMC Neurological Institute - Presbyterian

200 Lothrop Street, A402 UPMC Presbyterian, 
Pittsburgh, PA 
412-663-6733
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Gardner is the Peter J. Jannetta Endowed Chair of neurological surgery at the University of Pittsburgh School of Medicine and director of the Center for Skull Base Surgery. He specializes in endoscopic endonasal skull base surgery, pituitary tumors, Neuroendoport brain surgery, and vascular neurosurgery. Dr. Gardner is rated as an Elite provider by MediFind in the treatment of Meningioma. He is also highly rated in 61 other conditions, according to our data. His clinical expertise encompasses Chordoma, Pituitary Tumor, Meningioma, Nerve Decompression, and Endoscopic Transnasal Transsphenoidal Surgery. Dr. Gardner is board certified in American Board Of Neurological Surgery. Dr. Gardner is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Meningioma
Dr. Susan C. Pannullo
Neurosurgery | Neurology
Elite in Meningioma
Dr. Susan C. Pannullo
Neurosurgery | Neurology

Weill Cornell Medicine

525 East 68th Street, Suite 99, 
New York, NY 
212-746-2438
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Susan Pannullo is a Neurologist and a Neurosurgery provider practicing medicine in New York, New York. Dr. Pannullo is rated as an Elite provider by MediFind in the treatment of Meningioma. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Meningioma, Acoustic Neuroma, Metastatic Brain Tumor, and Brain Tumor. Dr. Pannullo is board certified in American Board Of Psychiatry And Neurology. Dr. Pannullo is currently accepting new patients.

View All Doctors
What are the latest Meningioma Clinical Trials?
MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma
MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Other, Drug
Study Phase: Phase 2

Summary: This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 11, 2022
Published By: Genetic and Rare Diseases Informnation Center